Rosiglitazone-associated fractures in type 2 diabetes: an Analysis from A Diabetes Outcome Progression Trial (ADOPT) - PubMed (original) (raw)
Randomized Controlled Trial
doi: 10.2337/dc07-2270. Epub 2008 Jan 25.
Collaborators, Affiliations
- PMID: 18223031
- DOI: 10.2337/dc07-2270
Free article
Randomized Controlled Trial
Rosiglitazone-associated fractures in type 2 diabetes: an Analysis from A Diabetes Outcome Progression Trial (ADOPT)
Steven E Kahn et al. Diabetes Care. 2008 May.
Free article
Abstract
Objective: The purpose of this study was to examine possible factors associated with the increased risk of fractures observed with rosiglitazone in A Diabetes Outcome Progression Trial (ADOPT).
Research design and methods: Data from the 1,840 women and 2,511 men randomly assigned in ADOPT to rosiglitazone, metformin, or glyburide for a median of 4.0 years were examined with respect to time to first fracture, rates of occurrence, and sites of fractures.
Results: In men, fracture rates did not differ between treatment groups. In women, at least one fracture was reported with rosiglitazone in 60 patients (9.3% of patients, 2.74 per 100 patient-years), metformin in 30 patients (5.1%, 1.54 per 100 patient-years), and glyburide in 21 patients (3.5%, 1.29 per 100 patient-years). The cumulative incidence (95% CI) of fractures in women at 5 years was 15.1% (11.2-19.1) with rosiglitazone, 7.3% (4.4-10.1) with metformin, and 7.7% (3.7-11.7) with glyburide, representing hazard ratios (95% CI) of 1.81 (1.17-2.80) and 2.13 (1.30-3.51) for rosiglitazone compared with metformin and glyburide, respectively. The increase in fractures with rosiglitazone occurred in pre- and postmenopausal women, and fractures were seen predominantly in the lower and upper limbs. No particular risk factor underlying the increased fractures in female patients who received rosiglitazone therapy was identified.
Conclusions: Further investigation into the risk factors and underlying pathophysiology for the increased fracture rate in women taking rosiglitazone is required to relate them to preclinical data and better understand the clinical implications of and possible interventions for these findings.
Trial registration: ClinicalTrials.gov NCT00279045.
Similar articles
- Effect of rosiglitazone, metformin, and glyburide on bone biomarkers in patients with type 2 diabetes.
Zinman B, Haffner SM, Herman WH, Holman RR, Lachin JM, Kravitz BG, Paul G, Jones NP, Aftring RP, Viberti G, Kahn SE; ADOPT Study Group. Zinman B, et al. J Clin Endocrinol Metab. 2010 Jan;95(1):134-42. doi: 10.1210/jc.2009-0572. Epub 2009 Oct 29. J Clin Endocrinol Metab. 2010. PMID: 19875477 Clinical Trial. - Thiazolidinediones and fractures in men and women.
Dormuth CR, Carney G, Carleton B, Bassett K, Wright JM. Dormuth CR, et al. Arch Intern Med. 2009 Aug 10;169(15):1395-402. doi: 10.1001/archinternmed.2009.214. Arch Intern Med. 2009. PMID: 19667303 - Vertebral fractures in males with type 2 diabetes treated with rosiglitazone.
Mancini T, Mazziotti G, Doga M, Carpinteri R, Simetovic N, Vescovi PP, Giustina A. Mancini T, et al. Bone. 2009 Oct;45(4):784-8. doi: 10.1016/j.bone.2009.06.006. Epub 2009 Jun 13. Bone. 2009. PMID: 19527806 - Thiazolidinediones: effects on the development and progression of type 2 diabetes and associated vascular complications.
Krentz A. Krentz A. Diabetes Metab Res Rev. 2009 Feb;25(2):112-26. doi: 10.1002/dmrr.937. Diabetes Metab Res Rev. 2009. PMID: 19219860 Review. - Oral antidiabetic agents in pregnancy and lactation: a paradigm shift?
Feig DS, Briggs GG, Koren G. Feig DS, et al. Ann Pharmacother. 2007 Jul;41(7):1174-80. doi: 10.1345/aph.1K045. Epub 2007 May 29. Ann Pharmacother. 2007. PMID: 17535842 Review.
Cited by
- The effect of thiazolidinediones on bone mineral density and bone turnover: systematic review and meta-analysis.
Billington EO, Grey A, Bolland MJ. Billington EO, et al. Diabetologia. 2015 Oct;58(10):2238-46. doi: 10.1007/s00125-015-3660-2. Epub 2015 Jun 25. Diabetologia. 2015. PMID: 26109213 Review. - Metformin: Is It the Well Wisher of Bone Beyond Glycemic Control in Diabetes Mellitus?
Shaik AR, Singh P, Shaik C, Kohli S, Vohora D, Ferrari SL. Shaik AR, et al. Calcif Tissue Int. 2021 Jun;108(6):693-707. doi: 10.1007/s00223-021-00805-8. Epub 2021 Apr 2. Calcif Tissue Int. 2021. PMID: 33797562 Review. - The pathophysiology of osteoporosis in obesity and type 2 diabetes in aging women and men: The mechanisms and roles of increased bone marrow adiposity.
Ali D, Tencerova M, Figeac F, Kassem M, Jafari A. Ali D, et al. Front Endocrinol (Lausanne). 2022 Sep 15;13:981487. doi: 10.3389/fendo.2022.981487. eCollection 2022. Front Endocrinol (Lausanne). 2022. PMID: 36187112 Free PMC article. Review. - THE EFFECT OF GLUCOVANCE THERAPY ON BIOMECHANICAL DETERIORATION OF BONE IN STREPTOZOTOCIN-INDUCED DIABETIC RATS.
Demirel C, Korkmaz H, Gurgul S, Yildiz A, Akarsu E, Erdal N. Demirel C, et al. Acta Endocrinol (Buchar). 2019 Jul-Sep;15(3):301-304. doi: 10.4183/aeb.2019.301. Acta Endocrinol (Buchar). 2019. PMID: 32010347 Free PMC article. - The Impact of Type 2 Diabetes on Bone Fracture Healing.
Marin C, Luyten FP, Van der Schueren B, Kerckhofs G, Vandamme K. Marin C, et al. Front Endocrinol (Lausanne). 2018 Jan 24;9:6. doi: 10.3389/fendo.2018.00006. eCollection 2018. Front Endocrinol (Lausanne). 2018. PMID: 29416527 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical